Cu-62 ATSM PET/CT tests for thoracic an head and neck malignant tumors

Cu-62 ATSM PET/CT tests for thoracic an head and neck malignant tumors - ATSM PET for thoracic and H&N tumors

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016369

Enrollment

Registered

2015-02-01

Start date

2015-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thoracic malignalt tumors head and neck malignant tumors

Interventions

ATSM PET/CT test

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) thoracic and head and neck malignant tumors diagnosed histopathologically or clinically 2) radiotherapy or chemoradiotherapy is considered at NationalCancer Center East 3) tolerable for PET/CT tests (PS 0-1) 4) written informed concent is obtained

Exclusion criteria

Exclusion criteria: Cases judged unsuitable by medical doctors

Design outcomes

Primary

Measure	Time frame
index for tumor uptake of ATSM CT number in tumors on ATSM PET/CT test Therapeutic effects Date of reccurence and/or death	—

Countries

Japan

Contacts

Public ContactHirofumi Fujii

National Cancer Center Hospital East Division of Functional Imaging

hifujii@east.ncc.go.jp04-7134-6832

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026